Determining the Minimally Effective Dose of a Clinical Candidate AAV Vector in a Mouse Model of Crigler-Najjar Syndrome

Liver metabolism disorders are attractive targets for gene therapy, because low vector doses can reverse the buildup of toxic metabolites in the blood. Crigler-Najjar syndrome is an inherited disorder of bilirubin metabolism that is caused by the absence of uridine diphosphate glucuronosyl transfera...

Descripción completa

Detalles Bibliográficos
Autores principales: Greig, Jenny A., Nordin, Jayme M.L., Draper, Christine, McMenamin, Deirdre, Chroscinski, Edward A., Bell, Peter, Gray, John T., Richman, Laura K., Wilson, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090885/
https://www.ncbi.nlm.nih.gov/pubmed/30112420
http://dx.doi.org/10.1016/j.omtm.2018.07.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090885/
https://www.ncbi.nlm.nih.gov/pubmed/30112420
http://dx.doi.org/10.1016/j.omtm.2018.07.008

Ejemplares similares